Company intelligence / Profile preview

NIOX Group

Oxford, England, United Kingdom

Ownership: Public · NIOX
Employees: ~84
Development stage: Commercial

Overview

NIOX’s FeNO measurement devices are commercially available and widely used globally as a gold standard for non-invasive assessment of airway inflammation to aid asthma diagnosis and management. Over 50 million tests have been performed worldwide. The technology assists clinicians in diagnosing asthma, determining responsiveness to inhaled corticosteroids, tailoring steroid use, monitoring treatment compliance, and reducing exacerbation risk compared to traditional monitoring methods[1][2][8].

Therapeutic areas: Pulmonology
Modalities: Device (FeNO measurement device)Non-pharmacological therapy (diagnostic/monitoring tool)
Industry: Physiological Monitoring

Drug pipeline

1 asset

NIOX VERO

Commercial

Indications: Asthma

Partnerships

AstraZeneca (historical COPD collaboration)ZEPHYRx (integration with cloud-based respiratory research platform)

Beyond the preview

Go deeper on NIOX Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIOX Group.

Explore the full profile